Top-News

PhaseRx News

Aktie
WKN:  A2AL53 ISIN:  US71723F1030 US-Symbol:  PZRXQ
Keine aktuellen Kursdaten verfügbar
Handeln Depot/Watchlist
Dieses Wertpapier ist nicht mehr handelbar.
Aktienanzahl *
11,69 Mio.
Marktkapitalisierung *
-
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 05.12.2017

PhaseRx News

13.12.17 - PR Newswire
PhaseRx Receives Decision from the Nasdaq Hearings Panel for Continued Listing of Shares
PhaseRx Receives Decision from the Nasdaq Hearings Panel for Continued Listing of Shares PR Newswire
11.12.17 - PR Newswire
PhaseRx Commences Voluntary Chapter 11 Bankruptcy Protection Proceeding
PhaseRx Commences Voluntary Chapter 11 Bankruptcy Protection Proceeding PR Newswire
28.11.17 - PR Newswire
PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-ASL from European Medicines Agency
PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-ASL from European Medicines Agency PR Newswire
09.11.17 - PR Newswire
PhaseRx Reports Third Quarter 2017 Financial Results and Provides Corporate Update
PhaseRx Reports Third Quarter 2017 Financial Results and Provides Corporate Update PR Newswire
31.10.17 - PR Newswire
PhaseRx to Present at 5th International mRNA Conference
PhaseRx to Present at 5th International mRNA Conference PR Newswire
26.10.17 - PR Newswire
PhaseRx Receives Delisting Notice from Nasdaq and Evaluates Listing Options
PhaseRx Receives Delisting Notice from Nasdaq and Evaluates Listing Options PR Newswire
13.10.17 - PR Newswire
PhaseRx Announces Corporate Restructuring and Review of Strategic Alternatives
PhaseRx Announces Corporate Restructuring and Review of Strategic Alternatives PR Newswire
20.09.17 - PR Newswire
PhaseRx Receives Orphan Drug Designation from FDA for PRX-ASL for the Treatment of Argininosuccinate Lyase Deficiency
PhaseRx Receives Orphan Drug Designation from FDA for PRX-ASL for the Treatment of Argininosuccinate Lyase Deficiency PhaseRx's second enzyme replacement therapy to ...
10.08.17 - PR Newswire
PhaseRx Reports Second Quarter 2017 Financial Results and Provides Corporate Update
PhaseRx Reports Second Quarter 2017 Financial Results and Provides Corporate Update PR Newswire
12.05.17 - PR Newswire
PhaseRx Reports First Quarter 2017 Financial Results and Provides Corporate Update
PhaseRx Reports First Quarter 2017 Financial Results and Provides Corporate Update PR Newswire
03.05.17 - PR Newswire
PhaseRx to Present Data at the American Society of Gene & Cell Therapy 20th Annual Meeting
PhaseRx to Present Data at the American Society of Gene & Cell Therapy 20th Annual Meeting PR Newswire
27.04.17 - PR Newswire
PhaseRx to Present Data at the TIDES Conference
PhaseRx to Present Data at the TIDES Conference PR Newswire
25.04.17 - PR Newswire
PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-OTC from European Medicines Agency
PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-OTC from European Medicines Agency PR Newswire
25.04.17 - PR Newswire
PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-OTC from European Medicines Agency
PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-OTC from European Medicines Agency PR Newswire
27.03.17 - PR Newswire
PhaseRx Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
PhaseRx Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update PR Newswire
27.02.17 - PR Newswire
PhaseRx to Present at Upcoming Investor Conferences
PhaseRx to Present at Upcoming Investor Conferences PR Newswire
08.02.17 - PR Newswire
PhaseRx to Present Data for PRX-OTC at the 13th Annual WORLDSymposium™ 2017
PhaseRx to Present Data for PRX-OTC at the 13th Annual WORLDSymposium™ 2017 PR Newswire
04.01.17 - PR Newswire
PhaseRx to Present at Biotech Showcase 2017
PhaseRx to Present at Biotech Showcase 2017 PR Newswire
28.11.16 - PR Newswire
PhaseRx Receives Orphan Drug Designation from FDA for PRX-OTC for the Treatment of Ornithine Transcarbamylase Deficiency
PhaseRx Receives Orphan Drug Designation from FDA for PRX-OTC for the Treatment of Ornithine Transcarbamylase Deficiency On track to file investigational new drug (IND) ...
08.11.16 - PR Newswire
PhaseRx Announces Positive Safety Results from Large Animal Study with Hybrid mRNA Delivery Technology
PhaseRx Announces Positive Safety Results from Large Animal Study with Hybrid mRNA Delivery Technology PR Newswire

Newssuche

Videos

17.05.24 +14,15%
Technical Trading: Gold Long-​Chance
Gold Long Typ: Turbo Open End WKN: VD1G7Y Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »